Combination chemotherapy in advanced small bowel adenocarcinoma

Oncology

Volumn 69, Issue 4, 2005, Pages 290-294

  Locher, Christophe ^a   Malka, David ^a   Boige, Valérie ^a   Lebray, Pascal ^a   Elias, Dominique ^a   Lasser, Philippe ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

5 Fluorouracil; Chemotherapy; Irinotecan; Platinum compounds; Small bowel adenocarcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CORONARY ARTERY SPASM; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; SMALL INTESTINE CARCINOMA; SURVIVAL TIME; TOXICITY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 28644442243     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089678     Document Type: Review

References (21)

1. Neugut AI, Marvin MR, Relia VA, Chabot JA: An overview of adenocarcinoma of the small intestine. Oncology 1997;21:529-536.
2. Green PH, Jabri B: Celiac disease and other precursors to small-bowel malignancy. Gastroenterol Clin North Am 2002;31:625-639.
3. Crawley C, Ross P, Norman A, Hill A, Cunningham D: The Royal Marsden experience of small bowel adenocarcinoma treated with 5-fluorouracil. Br J Cancer 1998;78:508-510.
4. Barraya R, Benhamiche AM, Rassiat E, Phelip JM, Jouve JL, Faivre J: Incidence et modalités de la prise en charge des cancers de l'intestin grêle en Bourgogne. Gastroenterol Clin Biol 1999;23:215-220.
5. Kummar S, Ciesielski TE, Fogarasi MC: Management of small bowel adenocarcinoma. Oncology (Huntingt) 2002;16:1364-1373.
6. Talamonti MS, Goetz LH, Rao S, Joehl RJ: Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002;137:564-571.
7. Cunningham JD, Aleali R, Aleali M, Brower ST, Aufses AH: Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann Surg 1997;225:300-306.
8. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D, et al: Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. Eur J Cancer 1994;30A:1263-1269.
9. Mitry E, Taieb J, Artru P, Boige V, Vaillant JN, Clavero-Fabri MC, Ducreux M, Rougier P: Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol 2004;15:765-769.
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
11. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
12. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
14. Kaplan ES, Meier PM: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457.
15. National Cancer Institute: Guidelines for Reporting Adverse Drug Reactions. Bethesda, Division of Cancer Treatment, National Cancer Institute, 1988.
16. Jigyasu D, Bedikian AY, Stroehlein JR: Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984;53:23-25.
17. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J: Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518-526.
18. Czaykowski P, Hui D: Chemotherapy for small bowel adenocarcinoma (SBA): experience over a 10-year period at the BC Cancer Agency (abstract 109). Gastrointestinal Cancers Symposium, San Francisco, 2004.
19. Polyzos A, Bramis J, Delladetsima JK, Sfikakis PP: Prolonged survival in metastatic adenocarcinoma of the small intestine treated with irinotecan. Clin Drug Invest 1999;18:79-83.
20. Jaskowiak NT, Michelassi F: Adenocarcinoma at a stricturoplasty site in Crohn's disease: report of a case. Dis Colon Rectum 2001;44:284-287.
21. Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M: Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004;15:1558-1565.